Nanobiotix S.A.
Nanobiotix develops JNJ-1900, a hafnium oxide nanoparticle injected into tumors and activated by radiotherapy to trigger tumor cell death and immune response.
6-KNov 12Latest SEC filing
Oct 28Latest story
Nanobiotix develops JNJ-1900, a hafnium oxide nanoparticle injected into tumors and activated by radiotherapy to trigger tumor cell death and immune response.